Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Ferrero

Showing results (411-420 of 481) with videos related to

Pageof 49
Sort By:
Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Haematologica|December 31, 2011
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Daniela Capello, Mirija Svaldi, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Hemasphere|January 22, 2026
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trialSimone Ragaini, Elisa Genuardi, Beatrice Alessandria, et al.
British Journal of Haematology|November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trialGiulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
Scientific Reports|December 11, 2021
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematologyGian Maria Zaccaria, Vito Colella, Simona Colucci, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
Pageof 49

Showing results (411-420 of 481) with videos related to

Sort By:
Pageof 49
Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Haematologica|December 31, 2011
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Daniela Capello, Mirija Svaldi, et al.
American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
Hemasphere|January 22, 2026
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trialSimone Ragaini, Elisa Genuardi, Beatrice Alessandria, et al.
British Journal of Haematology|November 28, 2024
Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trialGiulia Benevolo, Daniela Drandi, Nicoletta Villivà, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
Scientific Reports|December 11, 2021
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematologyGian Maria Zaccaria, Vito Colella, Simona Colucci, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
Pageof 49